Ieramilimab
Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.[1]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | LAG525 |
| Identifiers | |
| CAS Number | |
| UNII | |
Ieramilimab's first clinical trial is a Phase I in expected to be in patients with various solid tumors, in combination with PDR001, an anti-PD-1 monoclonal antibody. (ClinicalTrials.gov identifier NCT02460224).
References
- "Meet Novartis Management presentation, 17/18 June 2015" (PDF). Novartis. Retrieved 9 July 2015.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.